Managed care MCR
After two years of elevated medical costs, the medical care ratio printed multi-quarter lows in the second quarter. Whether that is a cycle turn or a one-time redesign is the open question.
UnitedHealth Group's Q2 2026 medical care ratio — medical costs divided by premiums — fell to 86.7%, down 270 basis points year-over-year from 89.4%. That is an eight-quarter low. Elevance Health confirmed the signal is sector-wide. The managed-care group beat, raised guidance, and re-rated. The dated evidence is two second-quarter earnings prints from one July pass — not a multi-year cost-cycle book.
What printed
UnitedHealth reported adjusted EPS of $6.38 versus roughly $4.91 consensus, revenue of $112.0 billion. Management attributed the MCR improvement to benefit redesign, tighter medical management, better-aligned pricing, and exits from unprofitable ACA and Medicare Advantage markets. Full-year adjusted EPS guidance rose to $19.50–$20.00 from greater than $18.25; MCR outlook improved to 88.1% plus or minus 25 basis points.
Elevance posted adjusted EPS of $7.45 versus $6.21 consensus on revenue of $49.8 billion, raising its full-year guide to at least $27.00.
UNH medical care ratio
UnitedHealth Group Q2 2026. Eight-quarter low.
Sentiment turned in early June — Humana up 6%, UnitedHealth up 5%, Cigna up 4% — on softer medical-cost trends, with Morgan Stanley, Bank of America, and Truist raising UnitedHealth targets on moderating utilization and AI efficiency.
Why the turn may not hold
UnitedHealth's own Q2 call flagged commercial medical cost trend "modestly above 11%" and Medicare "well above historical levels." The earnings strength is not coming from the insurance book's cost side — it is benefit redesign, market exits, and productivity. A re-acceleration could re-invert the MCR.
Elevance flagged elevated Medicaid costs — behavioral health, specialty pharmacy, outpatient surgery, emergency-department utilization — calling 2026 the trough year for Medicaid. Medicaid-heavy names like Centene and Molina do not share the commercial and Medicare Advantage tailwind. UnitedHealth also noted 2026 industry Stars scores at the lowest in about a decade — a multi-year Medicare Advantage revenue headwind independent of near-term MCR.
The falsifier is Medicaid-cost re-acceleration spreading to commercial books, or the beats proving driven by one-time reserve development and market exits rather than durable utilization moderation. The wiki does not yet resolve which.